Lanean...
Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia
AIMS: To assess the dose selection using population pharmacokinetics of Pegylated Intron-α2b (PEG-Intron) in patients with chronic myelogenous leukaemia (CML). METHODS: PEG-Intron 3–6 µg kg(−1) was administered subcutaneously once a week and blood samples were collected up to 48 weeks of treatment....
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Blackwell Science Inc
2007
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2000735/ https://ncbi.nlm.nih.gov/pubmed/16939523 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02757.x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|